Ainos, Inc. (NASDAQ:AIMD) Sees Significant Decline in Short Interest

Ainos, Inc. (NASDAQ:AIMD) was the target of a large decline in short interest in March. As of March 13th, there was short interest totaling 32,693 shares, a decline of 60.9% from the February 26th total of 83,517 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 27,436 shares, the days-to-cover ratio is currently 1.2 days.

Insiders Place Their Bets

In other Ainos news, major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the company’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $2.17, for a total value of $99,820.00. Following the sale, the insider directly owned 989,925 shares in the company, valued at $2,148,137.25. This represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 47,281 shares of company stock valued at $102,152 in the last quarter. Corporate insiders own 9.79% of the company’s stock.

Institutional Trading of Ainos

Hedge funds have recently modified their holdings of the stock. Mariner LLC acquired a new stake in shares of Ainos in the fourth quarter valued at approximately $37,000. DRW Securities LLC lifted its holdings in Ainos by 272.6% during the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after buying an additional 48,439 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Ainos by 13.1% during the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after buying an additional 7,700 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in Ainos in the 3rd quarter valued at $80,000.

Ainos Stock Down 1.4%

Shares of NASDAQ:AIMD opened at $1.44 on Thursday. Ainos has a 12 month low of $1.26 and a 12 month high of $4.50. The company’s 50-day moving average price is $1.67 and its two-hundred day moving average price is $2.42. The company has a quick ratio of 2.67, a current ratio of 2.96 and a debt-to-equity ratio of 1.10. The firm has a market cap of $6.93 million, a P/E ratio of -0.36 and a beta of 2.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Ainos in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Ainos presently has an average rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.